BioCryst Pharmaceuticals BCRX Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's stock issuance proceeds?
- BioCryst Pharmaceuticals (BCRX) reported stock issuance proceeds of $19.48M in Q1 2026.
- How has BioCryst Pharmaceuticals's stock issuance proceeds changed year-over-year?
- BioCryst Pharmaceuticals's stock issuance proceeds increased by 715.0% year-over-year, from $2.39M to $19.48M.
- What is the long-term trend for BioCryst Pharmaceuticals's stock issuance proceeds?
- Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's stock issuance proceeds has grown at a -43.3% compound annual growth rate (CAGR), from $50M to $9.12M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.